Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 225

1.

PET imaging of dopamine-D2 receptor internalization in schizophrenia.

Weinstein JJ, van de Giessen E, Rosengard RJ, Xu X, Ojeil N, Brucato G, Gil RB, Kegeles LS, Laruelle M, Slifstein M, Abi-Dargham A.

Mol Psychiatry. 2017 Jul 25. doi: 10.1038/mp.2017.157. [Epub ahead of print]

PMID:
29155803
2.

PET imaging of dopamine-D2 receptor internalization in schizophrenia.

Weinstein JJ, van de Giessen E, Rosengard RJ, Xu X, Ojeil N, Brucato G, Gil RB, Kegeles LS, Laruelle M, Slifstein M, Abi-Dargham A.

Mol Psychiatry. 2018 Jun;23(6):1506-1511. doi: 10.1038/mp.2017.107. Epub 2017 May 16. Erratum in: Mol Psychiatry. 2017 Jul 25;:.

3.

Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain.

Nabulsi NB, Mercier J, Holden D, Carré S, Najafzadeh S, Vandergeten MC, Lin SF, Deo A, Price N, Wood M, Lara-Jaime T, Montel F, Laruelle M, Carson RE, Hannestad J, Huang Y.

J Nucl Med. 2016 May;57(5):777-84. doi: 10.2967/jnumed.115.168179. Epub 2016 Feb 4.

4.

Posterior Reversible Encephalopathy Syndrome Associated with Sorafenib and Successful Retreatment.

Laruelle M, Filleul B, Duprez T, Machiels JP.

Urol Int. 2018;100(3):357-360. doi: 10.1159/000443970. Epub 2016 Feb 5.

PMID:
26845702
5.

Human Kinetic Modeling of the 5HT6 PET Radioligand 11C-GSK215083 and Its Utility for Determining Occupancy at Both 5HT6 and 5HT2A Receptors by SB742457 as a Potential Therapeutic Mechanism of Action in Alzheimer Disease.

Parker CA, Rabiner EA, Gunn RN, Searle G, Martarello L, Comley RA, Davy M, Wilson AA, Houle S, Mizrahi R, Laruelle M, Cunningham VJ.

J Nucl Med. 2015 Dec;56(12):1901-9. doi: 10.2967/jnumed.115.162743. Epub 2015 Sep 17.

6.

An evaluation of the brain distribution of [(11)C]GSK1034702, a muscarinic-1 (M 1) positive allosteric modulator in the living human brain using positron emission tomography.

Ridler K, Cunningham V, Huiban M, Martarello L, Pampols-Maso S, Passchier J, Gunn RN, Searle G, Abi-Dargham A, Slifstein M, Watson J, Laruelle M, Rabiner EA.

EJNMMI Res. 2014 Dec;4(1):66. doi: 10.1186/s13550-014-0066-y. Epub 2014 Dec 5.

7.

Characterization in humans of 18F-MNI-444, a PET radiotracer for brain adenosine 2A receptors.

Barret O, Hannestad J, Vala C, Alagille D, Tavares A, Laruelle M, Jennings D, Marek K, Russell D, Seibyl J, Tamagnan G.

J Nucl Med. 2015 Apr;56(4):586-91. doi: 10.2967/jnumed.114.152546. Epub 2015 Feb 19.

8.

Adenosine 2A receptor occupancy by tozadenant and preladenant in rhesus monkeys.

Barret O, Hannestad J, Alagille D, Vala C, Tavares A, Papin C, Morley T, Fowles K, Lee H, Seibyl J, Tytgat D, Laruelle M, Tamagnan G.

J Nucl Med. 2014 Oct;55(10):1712-8. doi: 10.2967/jnumed.114.142067. Epub 2014 Jul 31.

9.

Unexpectedly high affinity of a novel histamine H(3) receptor antagonist, GSK239512, in vivo in human brain, determined using PET.

Ashworth S, Berges A, Rabiner EA, Wilson AA, Comley RA, Lai RY, Boardley R, Searle G, Gunn RN, Laruelle M, Cunningham VJ.

Br J Pharmacol. 2014 Mar;171(5):1241-9. doi: 10.1111/bph.12505.

10.

Schizophrenia: from dopaminergic to glutamatergic interventions.

Laruelle M.

Curr Opin Pharmacol. 2014 Feb;14:97-102. doi: 10.1016/j.coph.2014.01.001. Epub 2014 Feb 11. Review.

PMID:
24524997
11.

Relationship between glycine transporter 1 inhibition as measured with positron emission tomography and changes in cognitive performances in nonhuman primates.

Castner SA, Murthy NV, Ridler K, Herdon H, Roberts BM, Weinzimmer DP, Huang Y, Zheng MQ, Rabiner EA, Gunn RN, Carson RE, Williams GV, Laruelle M.

Neuropsychopharmacology. 2014 Nov;39(12):2742-9. doi: 10.1038/npp.2014.4. Epub 2014 Feb 3.

12.

D-dimer cut-off adjusted to age performs better for exclusion of pulmonary embolism in patients over 75 years.

Laruelle M, Descamps OS, Lesage V.

Acta Clin Belg. 2013 Jul-Aug;68(4):298-302.

PMID:
24455801
13.

Characterising the plasma-target occupancy relationship of the neurokinin antagonist GSK1144814 with PET.

Ridler K, Gunn RN, Searle GE, Barletta J, Passchier J, Dixson L, Hallett WA, Ashworth S, Gray FA, Burgess C, Poggesi I, Bullman JN, Ratti E, Laruelle MA, Rabiner EA.

J Psychopharmacol. 2014 Mar;28(3):244-53. doi: 10.1177/0269881113517953. Epub 2014 Jan 15.

PMID:
24429221
14.

Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD.

Ding YS, Naganawa M, Gallezot JD, Nabulsi N, Lin SF, Ropchan J, Weinzimmer D, McCarthy TJ, Carson RE, Huang Y, Laruelle M.

Neuroimage. 2014 Feb 1;86:164-71. doi: 10.1016/j.neuroimage.2013.08.001. Epub 2013 Aug 9.

PMID:
23933039
15.

The second revision of the dopamine theory of schizophrenia: implications for treatment and drug development.

Laruelle M.

Biol Psychiatry. 2013 Jul 15;74(2):80-1. doi: 10.1016/j.biopsych.2013.05.016. No abstract available.

PMID:
23809260
16.

Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography.

Comley RA, Salinas CA, Slifstein M, Petrone M, Marzano C, Bennacef I, Shotbolt P, Van der Aart J, Neve M, Iavarone L, Gomeni R, Laruelle M, Gray FA, Gunn RN, Rabiner EA.

J Pharmacol Exp Ther. 2013 Aug;346(2):311-7. doi: 10.1124/jpet.112.202895. Epub 2013 May 17.

PMID:
23685546
17.

Mathematical modelling of [¹¹C]-(+)-PHNO human competition studies.

Searle GE, Beaver JD, Tziortzi A, Comley RA, Bani M, Ghibellini G, Merlo-Pich E, Rabiner EA, Laruelle M, Gunn RN.

Neuroimage. 2013 Mar;68:119-32. doi: 10.1016/j.neuroimage.2012.11.033. Epub 2012 Nov 30.

PMID:
23207573
18.

Imaging changes in synaptic acetylcholine availability in living human subjects.

Esterlis I, Hannestad JO, Bois F, Sewell RA, Tyndale RF, Seibyl JP, Picciotto MR, Laruelle M, Carson RE, Cosgrove KP.

J Nucl Med. 2013 Jan;54(1):78-82. doi: 10.2967/jnumed.112.111922. Epub 2012 Nov 15.

19.

The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction.

Nathan PJ, Watson J, Lund J, Davies CH, Peters G, Dodds CM, Swirski B, Lawrence P, Bentley GD, O'Neill BV, Robertson J, Watson S, Jones GA, Maruff P, Croft RJ, Laruelle M, Bullmore ET.

Int J Neuropsychopharmacol. 2013 May;16(4):721-31. doi: 10.1017/S1461145712000752. Epub 2012 Aug 29.

PMID:
22932339
20.

Synthesis and characterization of two PET radioligands for the metabotropic glutamate 1 (mGlu1) receptor.

Huang Y, Narendran R, Bischoff F, Guo N, Bae SA, Hwang DR, Lesage AS, Laruelle M.

Synapse. 2012 Dec;66(12):1002-14. doi: 10.1002/syn.21606. Epub 2012 Sep 29. Erratum in: Synapse. 2013 Feb;67(2):109.

PMID:
22927303
21.

Sustained recreational use of ecstasy is associated with altered pre and postsynaptic markers of serotonin transmission in neocortical areas: a PET study with [¹¹C]DASB and [¹¹C]MDL 100907.

Urban NB, Girgis RR, Talbot PS, Kegeles LS, Xu X, Frankle WG, Hart CL, Slifstein M, Abi-Dargham A, Laruelle M.

Neuropsychopharmacology. 2012 May;37(6):1465-73. doi: 10.1038/npp.2011.332. Epub 2012 Feb 22.

22.

Computerized cognitive remediation training for schizophrenia: an open label, multi-site, multinational methodology study.

Murthy NV, Mahncke H, Wexler BE, Maruff P, Inamdar A, Zucchetto M, Lund J, Shabbir S, Shergill S, Keshavan M, Kapur S, Laruelle M, Alexander R.

Schizophr Res. 2012 Aug;139(1-3):87-91. doi: 10.1016/j.schres.2012.01.042. Epub 2012 Feb 18.

PMID:
22342330
23.

Combining PET biodistribution and equilibrium dialysis assays to assess the free brain concentration and BBB transport of CNS drugs.

Gunn RN, Summerfield SG, Salinas CA, Read KD, Guo Q, Searle GE, Parker CA, Jeffrey P, Laruelle M.

J Cereb Blood Flow Metab. 2012 May;32(5):874-83. doi: 10.1038/jcbfm.2012.1. Epub 2012 Jan 25.

24.

Radiosynthesis and characterization of 11C-GSK215083 as a PET radioligand for the 5-HT6 receptor.

Parker CA, Gunn RN, Rabiner EA, Slifstein M, Comley R, Salinas C, Johnson CN, Jakobsen S, Houle S, Laruelle M, Cunningham VJ, Martarello L.

J Nucl Med. 2012 Feb;53(2):295-303. doi: 10.2967/jnumed.111.093419. Epub 2012 Jan 5.

25.

Affinity and selectivity of [¹¹C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo.

Gallezot JD, Beaver JD, Gunn RN, Nabulsi N, Weinzimmer D, Singhal T, Slifstein M, Fowles K, Ding YS, Huang Y, Laruelle M, Carson RE, Rabiner EA.

Synapse. 2012 Jun;66(6):489-500. doi: 10.1002/syn.21535. Epub 2012 Feb 24.

PMID:
22213512
26.

The 5-HT(2A) receptor and serotonin transporter in Asperger's disorder: A PET study with [¹¹C]MDL 100907 and [¹¹C]DASB.

Girgis RR, Slifstein M, Xu X, Frankle WG, Anagnostou E, Wasserman S, Pepa L, Kolevzon A, Abi-Dargham A, Laruelle M, Hollander E.

Psychiatry Res. 2011 Dec 30;194(3):230-234. doi: 10.1016/j.pscychresns.2011.04.007. Epub 2011 Nov 12.

27.

Biodistribution and radiation dosimetry of the serotonin 5-HT₆ ligand [¹¹C]GSK215083 determined from human whole-body PET.

Comley RA, Salinas C, Mizrahi R, Vitcu I, Ng A, Hallett W, Keat N, Wilson AA, Rabiner EA, Laruelle M, Houle S.

Mol Imaging Biol. 2012 Aug;14(4):517-21. doi: 10.1007/s11307-011-0523-1.

PMID:
22076076
28.

Donepezil impairs memory in healthy older subjects: behavioural, EEG and simultaneous EEG/fMRI biomarkers.

Balsters JH, O'Connell RG, Martin MP, Galli A, Cassidy SM, Kilcullen SM, Delmonte S, Brennan S, Meaney JF, Fagan AJ, Bokde AL, Upton N, Lai R, Laruelle M, Lawlor B, Robertson IH.

PLoS One. 2011;6(9):e24126. doi: 10.1371/journal.pone.0024126. Epub 2011 Sep 8.

29.

Within-subject comparison of [(11)C]-(+)-PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans.

Shotbolt P, Tziortzi AC, Searle GE, Colasanti A, van der Aart J, Abanades S, Plisson C, Miller SR, Huiban M, Beaver JD, Gunn RN, Laruelle M, Rabiner EA.

J Cereb Blood Flow Metab. 2012 Jan;32(1):127-36. doi: 10.1038/jcbfm.2011.115. Epub 2011 Aug 31.

30.

Extended characterisation of the serotonin 2A (5-HT2A) receptor-selective PET radiotracer 11C-MDL100907 in humans: quantitative analysis, test-retest reproducibility, and vulnerability to endogenous 5-HT tone.

Talbot PS, Slifstein M, Hwang DR, Huang Y, Scher E, Abi-Dargham A, Laruelle M.

Neuroimage. 2012 Jan 2;59(1):271-85. doi: 10.1016/j.neuroimage.2011.07.001. Epub 2011 Jul 18.

31.

Increased prefrontal cortical D₁ receptors in drug naive patients with schizophrenia: a PET study with [¹¹C]NNC112.

Abi-Dargham A, Xu X, Thompson JL, Gil R, Kegeles LS, Urban N, Narendran R, Hwang DR, Laruelle M, Slifstein M.

J Psychopharmacol. 2012 Jun;26(6):794-805. doi: 10.1177/0269881111409265. Epub 2011 Jul 18.

PMID:
21768159
32.

Translational characterization of [11C]GSK931145, a PET ligand for the glycine transporter type 1.

Gunn RN, Murthy V, Catafau AM, Searle G, Bullich S, Slifstein M, Ouellet D, Zamuner S, Herance R, Salinas C, Pardo-Lozano R, Rabiner EA, Farre M, Laruelle M.

Synapse. 2011 Dec;65(12):1319-32. doi: 10.1002/syn.20966. Epub 2011 Aug 12.

PMID:
21688322
33.

Characterization of in vivo pharmacological properties and sensitivity to endogenous serotonin of [11C] P943: a positron emission tomography study in Papio anubis.

Ridler K, Plisson C, Rabiner EA, Gunn RN, Easwaramoorthy B, Abi-Dargham A, Laruelle M, Slifstein M.

Synapse. 2011 Nov;65(11):1119-27. doi: 10.1002/syn.20946. Epub 2011 May 19.

PMID:
21538549
34.

Evaluation of dopamine D₂/₃ specific binding in the cerebellum for the positron emission tomography radiotracer [¹¹C]FLB 457: implications for measuring cortical dopamine release.

Narendran R, Mason NS, Chen CM, Himes M, Keating P, May MA, Rabiner EA, Laruelle M, Mathis CA, Frankle WG.

Synapse. 2011 Oct;65(10):991-7. doi: 10.1002/syn.20926. Epub 2011 Apr 26.

35.

In vitro assessment of the agonist properties of the novel 5-HT1A receptor ligand, CUMI-101 (MMP), in rat brain tissue.

Hendry N, Christie I, Rabiner EA, Laruelle M, Watson J.

Nucl Med Biol. 2011 Feb;38(2):273-7. doi: 10.1016/j.nucmedbio.2010.08.003. Epub 2010 Dec 28.

PMID:
21315283
36.

Measurement of the serotonin 1A receptor availability in patients with schizophrenia during treatment with the antipsychotic medication ziprasidone.

Frankle WG, Lombardo I, Kegeles LS, Slifstein M, Martin JH, Huang Y, Hwang DR, Reich E, Cangiano C, Gil R, Abi-Dargham A, Laruelle M.

J Psychopharmacol. 2011 Jun;25(6):734-43. doi: 10.1177/0269881110388329. Epub 2010 Nov 25.

PMID:
21109614
37.

Prediction of repeat-dose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy.

Abanades S, van der Aart J, Barletta JA, Marzano C, Searle GE, Salinas CA, Ahmad JJ, Reiley RR, Pampols-Maso S, Zamuner S, Cunningham VJ, Rabiner EA, Laruelle MA, Gunn RN.

J Cereb Blood Flow Metab. 2011 Mar;31(3):944-52. doi: 10.1038/jcbfm.2010.175. Epub 2010 Oct 13.

38.

Biodistribution and radiation dosimetry of the glycine transporter-1 ligand 11C-GSK931145 determined from primate and human whole-body PET.

Bullich S, Slifstein M, Passchier J, Murthy NV, Kegeles LS, Kim JH, Xu X, Gunn RN, Herance R, Gispert JD, Gutiérrez A, Farré M, Laruelle M, Catafau AM.

Mol Imaging Biol. 2011 Aug;13(4):776-84. doi: 10.1007/s11307-010-0398-6.

PMID:
20730499
39.

Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography.

Kegeles LS, Slifstein M, Xu X, Urban N, Thompson JL, Moadel T, Harkavy-Friedman JM, Gil R, Laruelle M, Abi-Dargham A.

Biol Psychiatry. 2010 Oct 1;68(7):634-41. doi: 10.1016/j.biopsych.2010.05.027. Epub 2010 Jul 31.

40.

Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy.

Tziortzi AC, Searle GE, Tzimopoulou S, Salinas C, Beaver JD, Jenkinson M, Laruelle M, Rabiner EA, Gunn RN.

Neuroimage. 2011 Jan 1;54(1):264-77. doi: 10.1016/j.neuroimage.2010.06.044. Epub 2010 Jun 30.

PMID:
20600980
41.

Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist.

Searle G, Beaver JD, Comley RA, Bani M, Tziortzi A, Slifstein M, Mugnaini M, Griffante C, Wilson AA, Merlo-Pich E, Houle S, Gunn R, Rabiner EA, Laruelle M.

Biol Psychiatry. 2010 Aug 15;68(4):392-9. doi: 10.1016/j.biopsych.2010.04.038.

42.

Evaluation of 11C-GSK189254 as a novel radioligand for the H3 receptor in humans using PET.

Ashworth S, Rabiner EA, Gunn RN, Plisson C, Wilson AA, Comley RA, Lai RY, Gee AD, Laruelle M, Cunningham VJ.

J Nucl Med. 2010 Jul;51(7):1021-9. doi: 10.2967/jnumed.109.071753. Epub 2010 Jun 16.

43.

Positron emission tomography imaging of dopamine D₂/₃ receptors in the human cortex with [¹¹C]FLB 457: reproducibility studies.

Narendran R, Mason NS, May MA, Chen CM, Kendro S, Ridler K, Rabiner EA, Laruelle M, Mathis CA, Frankle WG.

Synapse. 2011 Jan;65(1):35-40. doi: 10.1002/syn.20813.

44.

Increased serotonin 2A receptor availability in the orbitofrontal cortex of physically aggressive personality disordered patients.

Rosell DR, Thompson JL, Slifstein M, Xu X, Frankle WG, New AS, Goodman M, Weinstein SR, Laruelle M, Abi-Dargham A, Siever LJ.

Biol Psychiatry. 2010 Jun 15;67(12):1154-62. doi: 10.1016/j.biopsych.2010.03.013.

45.

Serotonin transporter polymorphisms (SLC6A4 insertion/deletion and rs25531) do not affect the availability of 5-HTT to [11C] DASB binding in the living human brain.

Murthy NV, Selvaraj S, Cowen PJ, Bhagwagar Z, Riedel WJ, Peers P, Kennedy JL, Sahakian BJ, Laruelle MA, Rabiner EA, Grasby PM.

Neuroimage. 2010 Aug 1;52(1):50-4. doi: 10.1016/j.neuroimage.2010.04.032. Epub 2010 Apr 18.

PMID:
20406689
46.

Identification and evaluation of [11C]GSK931145 as a novel ligand for imaging the type 1 glycine transporter with positron emission tomography.

Passchier J, Gentile G, Porter R, Herdon H, Salinas C, Jakobsen S, Audrain H, Laruelle M, Gunn RN.

Synapse. 2010 Jul;64(7):542-9. doi: 10.1002/syn.20760.

PMID:
20196141
47.

Increased synaptic dopamine function in associative regions of the striatum in schizophrenia.

Kegeles LS, Abi-Dargham A, Frankle WG, Gil R, Cooper TB, Slifstein M, Hwang DR, Huang Y, Haber SN, Laruelle M.

Arch Gen Psychiatry. 2010 Mar;67(3):231-9. doi: 10.1001/archgenpsychiatry.2010.10.

PMID:
20194823
48.

Imaging the D3 receptor in humans in vivo using [11C](+)-PHNO positron emission tomography (PET).

Rabiner EA, Laruelle M.

Int J Neuropsychopharmacol. 2010 Apr;13(3):289-90. doi: 10.1017/S1461145710000088. Epub 2010 Feb 11. No abstract available.

PMID:
20149269
49.

Impact of scatter correction on D2 receptor occupancy measurements using 123I-IBZM SPECT: comparison to 11C-Raclopride PET.

Bullich S, Cot A, Gallego J, Gunn RN, Suárez M, Pavía J, Ros D, Laruelle M, Catafau AM.

Neuroimage. 2010 May 1;50(4):1511-8. doi: 10.1016/j.neuroimage.2010.01.013. Epub 2010 Jan 18.

PMID:
20083205
50.

Striatal and extrastriatal dopamine release measured with PET and [(18)F] fallypride.

Slifstein M, Kegeles LS, Xu X, Thompson JL, Urban N, Castrillon J, Hackett E, Bae SA, Laruelle M, Abi-Dargham A.

Synapse. 2010 May;64(5):350-62. doi: 10.1002/syn.20734.

Supplemental Content

Loading ...
Support Center